OGR1 Antibody

What is OGR1 and what is its molecular structure?

OGR1 (Ovarian Cancer G-Protein Coupled Receptor 1), also known as GPR68, is a proton-sensing G-protein coupled receptor involved in pH homeostasis. It has a molecular mass of approximately 41 kDa in its unmodified form . OGR1 is a membrane protein with seven transmembrane domains characteristic of GPCRs. When glycosylated, Western blot analyses show bands between 56,000–72,000 daltons, confirming post-translational modifications . The receptor mediates its action by association with G proteins that stimulate inositol phosphate (IP) production or Ca²⁺ mobilization . OGR1 also functions as a metastasis suppressor gene in prostate cancer, indicating its multifaceted biological roles .

How does OGR1 respond to changes in extracellular pH?

OGR1 functions as a pH sensor that detects decreases in extracellular pH during inflammation and other pathological conditions . The receptor exhibits a remarkable pH-dependent activation profile, being almost silent at pH 7.8 but becoming fully activated at pH 6.8 . This activation window corresponds to the physiological and pathological pH changes that occur during inflammation, tumor development, and tissue injury.

Immunocytochemical experiments reveal that pH changes trigger alterations in the subcellular localization of OGR1, including receptor internalization after stimulation . When designing experiments to investigate pH-dependent OGR1 responses, researchers should implement precise pH control systems, use appropriate buffers that maintain stable pH during the experiment, and consider employing pH-sensitive fluorescent proteins or dyes to correlate local pH changes with receptor activation and trafficking.

What signaling pathways are activated by OGR1?

OGR1 activation initiates multiple signaling cascades, with the specific pathways varying by cell type and context:

• G-protein coupled signaling: Upon activation by acidic pH, OGR1 primarily couples to Gq/11 proteins, leading to phospholipase C activation, inositol phosphate (IP) production, and subsequent intracellular Ca²⁺ mobilization .

• Osteoblastic signaling: In bone cells, OGR1 represents an osteoblastic pH sensor regulating cell-mediated responses to acidosis .

• Immune cell signaling: In immune cells, OGR1 influences T cell responses through effects on antigen-presenting cells and regulates nitric oxide production by macrophages .

When studying OGR1 signaling, researchers should employ multiple readouts including calcium flux (using ratiometric calcium indicators), inositol phosphate accumulation assays, and cell-specific functional assays to comprehensively characterize the receptor's activity in their system of interest.

Where is OGR1 expressed in normal tissues?

Comprehensive immunohistochemical studies have revealed distinct expression patterns of OGR1 in normal tissues:

• Pancreatic expression: OGR1 is prominently expressed in glucagon-producing islet cells of the pancreas .

• Gastrointestinal tract: Specific endocrine cells of the intestinal tract show OGR1 expression .

• Immune cells: Various immune cell populations express OGR1, which contributes to its role in modulating immune responses .

To accurately assess OGR1 expression patterns, researchers should use validated antibodies for immunohistochemistry, such as the rabbit monoclonal anti-human GPR68 antibody 16H23L16, which has been extensively characterized for tissue staining applications . Complementary techniques including qRT-PCR for mRNA quantification and Western blotting for protein detection should be employed to corroborate immunohistochemical findings.

How do I validate the specificity of an OGR1 antibody?

Rigorous validation of OGR1 antibody specificity is essential for generating reliable research data. A comprehensive validation approach should include:

• Expression system validation: Compare antibody reactivity between cells with confirmed OGR1 expression (e.g., transfected cells overexpressing OGR1) and negative control cells (mock-transfected). Western blot analysis should reveal specific bands at the expected molecular weight range of 56,000–72,000 for the glycosylated receptor .

• Gene silencing confirmation: Conduct siRNA knockdown experiments to demonstrate a reduction in antibody signal when OGR1 expression is diminished. For example, GPR68 expression in BON-1 cells has been successfully silenced by specific siRNA, resulting in a distinct decrease in immunosignal compared to cells transfected with scrambled siRNA .

• Multiple application testing: Validate the antibody across multiple applications (Western blot, immunohistochemistry, immunofluorescence) to ensure consistent specificity.

• Peptide competition: If the immunizing peptide is available, perform peptide competition assays where pre-incubation of the antibody with the peptide should abolish specific staining.

• Knockout validation: When possible, test the antibody on samples from OGR1-knockout models, which should show absence of specific staining.

What are the optimal applications for different OGR1 antibodies?

Different OGR1 antibodies exhibit variable performance across applications, making it crucial to select the appropriate antibody for specific research needs:

When selecting an antibody, researchers should carefully review validation data for their specific application, consider the host species to avoid cross-reactivity in multi-color staining, and evaluate epitope location which may affect accessibility in different applications.

How can I optimize immunohistochemical staining for OGR1 in FFPE tissues?

Optimizing immunohistochemical detection of OGR1 in formalin-fixed, paraffin-embedded (FFPE) tissues requires systematic refinement of multiple parameters:

• Antigen retrieval: Test both heat-induced epitope retrieval (HIER) methods:

  • Citrate buffer (pH 6.0) for 20-40 minutes

  • EDTA buffer (pH 9.0) for 20-40 minutes
    Compare results to determine optimal conditions for your specific antibody.

• Antibody dilution optimization: Perform a dilution series (typically 1:50 to 1:1000) to identify the concentration that maximizes specific staining while minimizing background.

• Incubation protocol development:

  • Test various incubation times (1 hour at room temperature vs. overnight at 4°C)

  • Evaluate blocking reagents to reduce non-specific binding

  • Optimize secondary antibody concentrations

• Signal amplification assessment: For low-abundance targets, evaluate signal amplification systems such as polymer-based detection or tyramide signal amplification.

• Counterstaining adjustment: Modify hematoxylin intensity to ensure nuclear detail without obscuring OGR1 signal.

The rabbit monoclonal anti-human GPR68 antibody 16H23L16 has been successfully applied to FFPE tissues, revealing OGR1 expression in specific cell populations including pancreatic neuroendocrine cells . This antibody represents a well-characterized reagent for OGR1 detection in clinical pathology samples.

What controls should I include when studying OGR1 in experimental systems?

A robust experimental design for OGR1 research requires comprehensive controls:

• Positive tissue controls:

  • Pancreatic tissue sections containing glucagon-producing islet cells

  • Intestinal tissue with documented OGR1-expressing endocrine cells

  • Pancreatic neuroendocrine tumors with known OGR1 expression

• Negative controls:

  • Primary antibody omission to assess detection system specificity

  • Isotype control antibodies to identify non-specific binding

  • Tissues or cells with confirmed absence of OGR1 expression

• Expression manipulation controls:

  • OGR1-overexpressing cells versus vector controls

  • siRNA knockdown samples (as demonstrated with GPR68-specific siRNA in BON-1 cells)

  • Tissues from OGR1-knockout animals when available

• pH-dependent activation controls:

  • Paired samples at pH 7.8 (minimal OGR1 activation) and pH 6.8 (maximal activation)

  • pH-insensitive receptor mutants if available

• Functional readout controls:

  • Positive controls for downstream signaling events (calcium flux, inositol phosphate production)

  • Inhibitors of OGR1 signaling pathway components as negative controls

How does OGR1 modulate autoimmune disease progression?

OGR1 plays a significant role in autoimmune disease pathogenesis, particularly in experimental autoimmune encephalomyelitis (EAE), an animal model of multiple sclerosis:

• Disease severity regulation: OGR1-knockout mice demonstrate a drastically attenuated clinical course of EAE compared to wild-type counterparts, indicating a pro-inflammatory role for OGR1 in this model .

• T cell response modulation: The reduced disease severity in OGR1-knockout mice correlates with a profound reduction in:

  • Expansion of myelin oligodendrocyte glycoprotein 35-55-reactive T helper 1 (Th1) cells

  • Development of pathogenic Th17 cells in the periphery

  • Accumulation of both Th1 and Th17 effector cells in the central nervous system

• Antigen-presenting cell dysfunction: OGR1-knockout mice exhibit:

  • Reduced frequency and absolute number of dendritic cells in draining lymph nodes during EAE (40% reduction in frequency and 75% reduction in total number)

  • Impaired capacity of antigen-presenting cells to support T cell proliferation

• Nitric oxide production enhancement: Macrophages from OGR1-knockout mice produce higher levels of nitric oxide, which may contribute to suppression of T cell responses .

These findings position OGR1 as a potential therapeutic target for T cell-mediated autoimmune diseases such as multiple sclerosis, where modulating the receptor's activity could attenuate pathogenic immune responses.

What is the role of OGR1 in cancer biology?

OGR1's function in cancer biology appears to be context-dependent, with evidence supporting both tumor-suppressive and tumor-promoting roles:

• Tumor suppression activity:

  • OGR1 functions as a metastasis suppressor gene in prostate cancer

  • Suppressive effects may involve inhibition of cancer cell migration and invasion

• Tumor promotion potential:

  • OGR1 may facilitate cancer cell adaptation to the acidic tumor microenvironment

  • Its pH-sensing capabilities could enable survival signaling under acidic conditions

• Contradictory evidence: Available literature indicates that "GPR68 can act as either a tumour suppressor or a tumour promoter" , suggesting that its effects are highly dependent on:

  • Cancer type and stage

  • Genetic and epigenetic context

  • Tumor microenvironment characteristics

• Expression in neuroendocrine tumors: GPR68 expression has been documented in pancreatic neuroendocrine tumors, suggesting potential roles in this cancer type .

To resolve these apparent contradictions, researchers should design experiments that carefully control for:

• Cell type and genetic background

• Extracellular pH conditions

• Tumor microenvironment factors

• Stage of tumor progression

Such controlled studies will help elucidate the specific contexts in which OGR1 exhibits tumor-suppressive versus tumor-promoting functions.

Which disease models are most appropriate for investigating OGR1 function?

Several disease models have proven valuable for elucidating OGR1's physiological and pathological roles:

• Experimental autoimmune encephalomyelitis (EAE):

  • Most extensively characterized model for OGR1 function

  • Allows comparison of disease course between wild-type and OGR1-knockout mice

  • Provides insights into OGR1's role in T cell autoimmunity

• Cancer models:

  • Syngeneic prostate tumor models have revealed reduced adaptive immune responses in OGR1-knockout mice

  • Pancreatic neuroendocrine tumor models may be valuable given OGR1 expression in these tumors

• Inflammation models:

  • OVA-induced sensitization/challenge model of asthma

  • IL-10-/- model of irritable bowel disease

• In vitro pH modulation systems:

  • Cell culture with precise pH control enables study of OGR1's pH-sensing functions

  • Allows investigation of receptor trafficking and signaling under defined conditions

When selecting a disease model, researchers should consider:

• The specific aspect of OGR1 biology under investigation

• Availability of appropriate controls (particularly OGR1-knockout animals)

• Relevance to human disease

• Technical feasibility of manipulating and measuring key parameters (pH, immune responses)

Careful model selection is critical for generating translatable insights into OGR1's role in human disease pathophysiology.

What phenotypic differences exist between OGR1-knockout and wild-type models?

OGR1-knockout models exhibit several distinctive phenotypic characteristics compared to wild-type counterparts:

• Immune system alterations:

  • Normal frequencies of lymphoid and myeloid cell populations under basal conditions

  • Significantly reduced frequency (40% reduction) and absolute number (75% reduction) of dendritic cells and macrophages in draining lymph nodes during inflammatory challenges

  • Impaired expansion of antigen-specific T helper cells during immune responses

  • Higher production of nitric oxide by macrophages in response to inflammatory stimuli

• Inflammatory response modifications:

  • Markedly attenuated clinical course of EAE with reduced central nervous system inflammation

  • Diminished antigen-specific recall responses as measured by T cell proliferation and cytokine production

  • Reduced inflammatory infiltrates in affected tissues during autoimmune challenges

• Antigen presentation deficiencies:

  • Antigen-presenting cells from OGR1-knockout mice show reduced capacity to stimulate T cell proliferation in co-culture experiments

  • Lower frequency of Th1 effector cell development in the presence of OGR1-deficient antigen-presenting cells

• Normal baseline physiology:

  • No reported major developmental or homeostatic abnormalities

  • Phenotypic differences emerge primarily during inflammatory or pathological challenges

These phenotypic differences highlight OGR1's particularly important role during stress or pathological conditions rather than during normal development or homeostasis, suggesting potential for therapeutic targeting with minimal impact on normal physiological functions.

How can experimental approaches resolve contradictory data regarding OGR1's role in tumor biology?

Resolving the apparent contradictions regarding OGR1's role in tumor biology requires sophisticated experimental design with careful attention to context-specificity:

• Cell-type specific analysis:

  • Implement parallel studies across multiple cell lines from the same cancer type

  • Compare OGR1 function in primary tumor cells versus metastatic derivatives

  • Assess OGR1 activity in tumor cells versus stromal components

• pH-dependent functional assessment:

  • Evaluate OGR1's effects under precisely controlled pH conditions (pH 7.8 vs. 6.8)

  • Measure multiple functional outcomes (proliferation, migration, invasion, survival)

  • Correlate functional outcomes with receptor activation state

• Signaling pathway interrogation:

  • Perform comprehensive phosphoproteomic analysis following OGR1 activation

  • Identify context-specific signaling partners that may direct tumor-suppressive versus tumor-promoting outcomes

  • Use pathway inhibitors to determine which downstream effectors mediate specific outcomes

• Genetic approaches:

  • Conduct domain-specific mutagenesis to separate different OGR1 functions

  • Develop tissue-specific and inducible OGR1 knockout models

  • Use CRISPR-Cas9 screening to identify genetic modifiers of OGR1 function

• Clinical correlation:

  • Stratify patient samples based on tumor microenvironment pH

  • Correlate OGR1 expression with clinical outcomes in well-annotated cohorts

  • Integrate genomic and transcriptomic data to identify patterns associated with differential OGR1 function

These approaches will help define the specific contexts in which OGR1 functions as a tumor suppressor versus tumor promoter, enabling more targeted therapeutic interventions.

What methodologies enable effective characterization of OGR1 trafficking in response to pH changes?

Studying OGR1 trafficking in response to pH changes requires specialized techniques that maintain receptor functionality while providing spatial and temporal resolution:

• Live-cell fluorescence microscopy:

  • Generate cells expressing fluorescently tagged OGR1 (e.g., OGR1-GFP fusion)

  • Implement perfusion systems for rapid and controlled pH changes

  • Use confocal or TIRF microscopy to visualize receptor translocation with high spatial resolution

  • Apply ratiometric imaging to simultaneously monitor pH changes and receptor movement

• pH-dependent conformational analysis:

  • Employ FRET-based biosensors to detect conformational changes upon pH-mediated activation

  • Design receptors with strategically placed fluorophores to report activation state

  • Measure dynamic changes in receptor conformation during pH transitions

• Selective surface labeling:

  • Use cell-impermeable biotinylation reagents to selectively label surface-exposed OGR1

  • Apply antibodies that recognize extracellular epitopes in non-permeabilized cells

  • Quantify internalization rates by measuring the ratio of surface to internalized receptor

• Subcellular fractionation approaches:

  • Perform density gradient fractionation to isolate plasma membrane, endosomal, and other compartments

  • Quantify OGR1 distribution across fractions by Western blotting

  • Track receptor movement between fractions in response to pH changes

• Super-resolution microscopy:

  • Apply STORM, PALM, or structured illumination microscopy for nanoscale localization

  • Use multi-color imaging to visualize OGR1 colocalization with endocytic markers

  • Implement particle tracking to analyze individual receptor trafficking events

The search results indicate that immunocytochemical experiments have revealed pH-dependent changes in subcellular localization of OGR1 and internalization after stimulation , confirming the value of these approaches for studying OGR1 trafficking dynamics.

What strategies can overcome technical challenges in detecting native OGR1 protein expression?

Detecting native OGR1 protein expression presents several technical challenges that can be addressed through methodological refinements:

• Antibody optimization:

  • Use well-characterized antibodies like the rabbit monoclonal anti-human GPR68 antibody 16H23L16, which has demonstrated specificity in Western blot and immunohistochemistry

  • Test multiple antibodies targeting different epitopes of OGR1

  • Optimize antibody concentration through careful titration experiments

• Signal amplification approaches:

  • Implement tyramide signal amplification for immunohistochemistry of low-abundance targets

  • Use high-sensitivity chemiluminescent substrates for Western blotting

  • Consider proximity ligation assays for detecting protein-protein interactions involving OGR1

• Sample preparation refinements:

  • For Western blotting: Include appropriate detergents for membrane protein solubilization

  • For immunohistochemistry: Test multiple fixation protocols and antigen retrieval methods

  • For flow cytometry: Optimize permeabilization conditions for intracellular epitopes

• Specificity controls:

  • Use OGR1-knockout tissues or cells as negative controls

  • Perform siRNA knockdown to confirm antibody specificity, as demonstrated in BON-1 cells

  • Include peptide competition controls when possible

• Alternative detection strategies:

  • Consider mass spectrometry-based approaches for unbiased protein detection

  • Use RNA detection methods (in situ hybridization, qRT-PCR) to corroborate protein findings

  • Develop activity-based probes that detect functional OGR1

By implementing these strategies, researchers can overcome the challenges associated with detecting native OGR1 expression and generate reliable data on receptor distribution and abundance across tissues and experimental conditions.

How can gene silencing approaches for OGR1 be optimized in primary cells?

Optimizing gene silencing of OGR1 in primary cells requires careful consideration of cell type characteristics, transfection sensitivity, and experimental timelines:

• siRNA-based approaches:

  • Design and test multiple siRNA sequences targeting different regions of OGR1 mRNA

  • Optimize transfection conditions for each primary cell type:

    • Electroporation for immune cells and neurons

    • Lipid-based transfection for adherent primary cells

    • Nucleofection for difficult-to-transfect primary cells

  • Validate knockdown efficiency at both mRNA (qRT-PCR) and protein (Western blot) levels

  • Include appropriate controls (scrambled siRNA) as demonstrated in GPR68 silencing experiments in BON-1 cells

• Viral vector delivery systems:

  • Develop lentiviral or adenoviral vectors expressing shRNA against OGR1

  • Optimize viral titer to achieve efficient transduction while minimizing toxicity

  • Consider using fluorescent reporters to identify and isolate transduced cells

  • Test different promoters to achieve appropriate expression levels

• CRISPR-Cas9 genome editing:

  • Design guide RNAs with high on-target and low off-target activity

  • Deliver as ribonucleoprotein complexes for transient Cas9 expression

  • Implement high-efficiency delivery methods specific to your primary cell type

  • Include comprehensive validation of editing efficiency and specificity

• Antisense oligonucleotide approaches:

  • Design modified oligonucleotides with enhanced stability and cell penetration

  • Test gymnotic delivery (without transfection reagents) for sensitive primary cells

  • Optimize oligonucleotide concentration and treatment duration

  • Monitor potential immunostimulatory effects, especially in immune cells

• Functional validation strategies:

  • Assess pH responsiveness (calcium flux, inositol phosphate production)

  • Measure cell-type specific functional outcomes (e.g., antigen presentation capacity in dendritic cells)

  • Consider rescue experiments with wild-type OGR1 to confirm specificity of observed effects

How does OGR1 regulate dendritic cell-T cell interactions in autoimmunity?

OGR1 plays a critical role in modulating dendritic cell-T cell interactions during autoimmune responses, as revealed by studies in experimental autoimmune encephalomyelitis (EAE):

• Dendritic cell dynamics in draining lymph nodes:

  • OGR1-knockout mice exhibit significantly reduced frequency (40% reduction) and total number (75% reduction) of CD11c+ dendritic cells in draining lymph nodes during EAE

  • This reduction occurs specifically during inflammatory conditions, as baseline dendritic cell populations are normal in naive OGR1-knockout mice

  • The mechanism may involve altered dendritic cell recruitment, retention, or survival in lymphoid tissues

• Antigen presentation capacity:

  • Antigen-presenting cells from OGR1-knockout mice demonstrate reduced ability to support T cell proliferation in co-culture experiments

  • OGR1-deficient antigen-presenting cells induce lower frequencies of Th1 effector cells compared to wild-type cells

  • This functional defect may stem from alterations in co-stimulatory molecule expression, cytokine production, or antigen processing

• T cell priming and differentiation:

  • OGR1 deficiency results in profoundly impaired antigen-specific T cell responses, as measured by recall proliferation to myelin oligodendrocyte glycoprotein peptide

  • Both Th1 and Th17 cell development are compromised in OGR1-knockout mice, with reduced IFN-γ and IL-17 production in response to antigen stimulation

  • The defect in T cell responses likely stems from upstream deficiencies in antigen-presenting cell function rather than intrinsic T cell abnormalities

• pH sensing in lymphoid microenvironments:

  • OGR1's function as a pH sensor may link local acidification during inflammation to enhanced antigen presentation

  • The pH optimum for OGR1 activation (pH 6.8) corresponds to acidification that occurs in inflammatory environments

Understanding these mechanisms provides insights into how OGR1 supports autoimmune T cell responses and identifies potential intervention points for therapeutic development.

What mechanisms underlie OGR1-mediated regulation of nitric oxide production in macrophages?

OGR1 negatively regulates nitric oxide (NO) production in macrophages through mechanisms that link pH sensing to inflammatory mediator production:

• Enhanced NO production in OGR1-deficient macrophages:

  • Macrophages from OGR1-knockout mice produce higher levels of nitric oxide in response to inflammatory stimuli compared to wild-type macrophages

  • This increase in NO production likely contributes to the impaired T cell responses observed in OGR1-knockout mice, as NO can inhibit T cell proliferation and function

• Potential molecular mechanisms:

  • OGR1 may normally suppress inducible nitric oxide synthase (iNOS) expression at the transcriptional level

  • OGR1-mediated calcium signaling could modulate post-translational regulation of NOS activity

  • OGR1 activation might influence key transcription factors controlling iNOS expression (NF-κB, STAT1)

• pH-dependent regulation:

  • Extracellular acidification during inflammation may activate OGR1, providing feedback regulation of NO production

  • The proton-sensing function of OGR1 could serve as a mechanism to link tissue pH to modulation of inflammatory mediator production

• Experimental approaches for mechanism investigation:

  • Compare iNOS mRNA and protein expression between wild-type and OGR1-knockout macrophages

  • Assess phosphorylation status of key signaling molecules (NF-κB, MAPK, STAT1) following inflammatory stimulation

  • Use pharmacological modulators of OGR1 to determine acute effects on NO production

  • Implement rescue experiments with wild-type and mutant OGR1 constructs

Understanding this regulatory mechanism could reveal new therapeutic approaches for conditions where dysregulated NO production contributes to pathology, such as autoimmune and inflammatory diseases.

How do pH fluctuations in inflammatory microenvironments influence OGR1-dependent immune responses?

pH fluctuations in inflammatory microenvironments dynamically modulate OGR1-dependent immune responses through several interconnected mechanisms:

• Receptor activation kinetics:

  • OGR1 exhibits a steep pH-dependent activation profile, being almost silent at pH 7.8 but fully activated at pH 6.8

  • This activation window precisely corresponds to the physiological pH changes that occur during inflammation

  • Local acidification in inflammatory sites would therefore trigger OGR1 activation specifically in these regions

• Receptor trafficking and localization:

  • pH changes induce alterations in subcellular localization of OGR1

  • Acidification triggers receptor internalization, potentially as a regulatory mechanism

  • This dynamic trafficking affects receptor availability at the cell surface and subsequent signaling capacity

• Cell type-specific responses:

  • Dendritic cells: pH-mediated OGR1 activation likely enhances maturation and antigen presentation capacity

  • Macrophages: OGR1 activation appears to suppress nitric oxide production

  • T cells: While not directly affected by OGR1, they respond to altered function of OGR1-expressing antigen-presenting cells

• Amplification of inflammatory cascades:

  • Initial inflammation causes local acidification

  • Acidification activates OGR1 on immune cells

  • OGR1 activation enhances antigen presentation and T cell responses

  • Expanded T cell responses further promote inflammation and acidification

This pH-sensing function positions OGR1 as a critical link between tissue microenvironment changes and immune cell function, allowing for context-specific modulation of inflammatory responses based on local conditions.

What experimental designs best evaluate OGR1 as a therapeutic target in autoimmune diseases?

Rigorous evaluation of OGR1 as a therapeutic target in autoimmune diseases requires multifaceted experimental approaches:

• Target validation in multiple disease models:

  • Extend studies beyond experimental autoimmune encephalomyelitis (EAE) to other autoimmune models:

    • Collagen-induced arthritis for rheumatoid arthritis

    • NOD mouse model for type 1 diabetes

    • Imiquimod-induced psoriasis model

  • Compare disease progression between wild-type and OGR1-knockout animals across these models

  • Determine whether the protective effects observed in EAE translate to other autoimmune conditions

• Therapeutic intervention approaches:

  • Develop small molecule antagonists of OGR1

  • Test therapeutic efficacy in both prevention and treatment paradigms:

    • Administration before disease induction (prevention)

    • Administration after disease onset (treatment)

  • Evaluate dose-response relationships and therapeutic windows

  • Compare efficacy to standard-of-care treatments for each disease

• Cellular and molecular mechanism studies:

  • Track dendritic cell numbers and function in lymphoid tissues during treatment

  • Assess T cell proliferation and differentiation in response to relevant antigens

  • Measure nitric oxide production by macrophages with and without intervention

  • Evaluate changes in local tissue pH and correlate with treatment response

• Safety and specificity assessment:

  • Determine effects on protective immunity using infection challenge models

  • Evaluate potential compensation by other pH-sensing receptors

  • Assess long-term consequences of OGR1 inhibition on immune homeostasis

  • Identify potential biomarkers for treatment response or adverse effects

• Translational considerations:

  • Evaluate OGR1 expression and function in human autoimmune disease samples

  • Develop humanized mouse models expressing human OGR1 for preclinical testing

  • Identify patient subpopulations most likely to benefit from OGR1-targeted therapy

These comprehensive experimental approaches will establish whether OGR1 represents a viable therapeutic target for autoimmune diseases and define the optimal strategies for clinical translation.